NEW YORK-- Shares of Ambit Biosciences tumbled Wednesday after the company said it won't file for accelerated approval of its leukemia drug quizartinib, and will run a late-stage clinical trial instead. The company has been meeting with the Food and Drug Administration to discuss quizartinib, a potential treatment for acute myeloid leukemia.» Read More
With the weight loss market heating up, stocks like Arena Pharmaceuticals may be spelling out a big rally for the drug retail space.
“Mad Money” host Jim Cramer has the answer.
Last week, Celgene announced it was pulling its Revlimid application in Europe, and Mad Money host Jim Cramer explains why he thinks investors should buy into the stock now.
A look at the impact of the Supreme Court's ruling on biotech stocks, with James Greenwood, BIO CEO.
Could Obamacare be a "legacy-killer" for Obama? David Goodfriend, former Clinton White House official, and Michael Medved, radio talk show host, share their opinions.
CNBC's John Harwood reports on the anticipation for the ruling on Obamacare tomorrow; and Edward Klein, Author of "The Amateur," weighs in. "If the Supreme Court rules against Obamacare, I think it will be a grievance blow to [Obama's] presidency," says Klein.
Discussing the impact the ruling of Obamacare could have on the economy, with Senator John Barrasso (R-WY); Ron Kruszewski, Stifel Nicolaus & Company CEO; and Michael Farr, Farr, Miller & Washington.
The biotech sector is up more than 1 percent today, and discussing what investors can expect after tomorrow's health care reform ruling, with ISI's biotech and pharmaceuticals major analyst Mark Schoenebaum. "If tomorrow the whole bill is struck down, technically, earnings and revenue estimates for all of biotech and all of pharma companies are going to go up," says Schoenebaum.
Shares of Arena Pharmaceuticals spiked on news the FDA approved its anti-obesity drug, with the Fast Money traders; and discussing how tomorrow's ruling on the health care reform could impact the biotech sector, with Mark Schoenebaum, ISI.
The "Mad Money" host spoke with the CEO of Seattle Genetics about the safety of the biotech space.
Daniel Junius, CEO of Immunogen, discusses drugs the company is developing.
Investors who jumped into U.S. Treasurys and the dollar during the latest flare-up of the EU crisis appear to have expanded into gold and other metals, according to a new report.
A few sectors have managed to gain ground during the past three weeks, and retail investors who took advantage of the right ETFs have something to show for it.
Faced with more service members returning without limbs from Iraq and Afghanistan, scientists, the government and private-sector companies are using new materials, tools and techniques to create sophisticated prostheses for amputees.
There is a great chance that Sirius XM Radio’s stock will hit $1.65 within the next several sessions — in other words, this is bound to get worse before it gets better.
Here’s a look at several under-$10 stocks that look poised to potentially trade higher from current levels.
Many jobs that let reserved types work in solitude offer poor salaries and unchallenging work. But there are other careers that are stimulating, well-paying and require little human contact.
We pulled together a list of Cramer's favorite dividend plays. Read on and pick one or two for your portfolio. They could offer just the kind of defense that you need.
There are too many options but no one solution to the energy problem. Our needs are many. The current alternative energies — solar, wind, biofuels, nuclear and geothermal — all have limitations, but they're worth it until something better comes along.
Sanofi-Aventis has been quick to move before its patents on bestselling products expired, said CEO Chris Viehbacher.